"Merck Exceeds Expectations with Strong Keytruda and Gardasil Sales"

Merck reported fourth-quarter revenue and adjusted earnings that beat expectations, driven by strong sales of its cancer drug Keytruda and HPV vaccine Gardasil. The company posted a net loss due to charges related to a deal with Daiichi Sankyo. Merck also issued its full-year 2024 guidance, which was generally in line with expectations, and announced a new restructuring program. Sales of Keytruda and Gardasil saw significant growth, while sales of its Covid antiviral pill Lagevrio and Type 2 diabetes treatment Januvia declined.